Dr Max Topp On The Tower Study And Blinatumomab In All Youtube Max s. topp, md, professor and head of haematology, university hospital of wuerzburg, germany, discusses the phase iii tower study, which looked at blinatumomab (blincyto) versus standard. Outcomes for adults with relapsed refractory acute lymphoblastic leukemia (all) are poor with chemotherapy, particularly in later salvage. the tower study examined survival, remission, bridge to allogeneic hematopoietic stem cell transplantation (hsct), and safety with blinatumomab versus chemothera ….
Dr Max Topp On The Tower Study And Blinatumomab In All Outcomes for adults with relapsed refractory acute lymphoblastic leukemia (all) are poor with chemotherapy, particularly in later salvage. the tower study examined survival, remission, bridge to allogeneic hematopoietic stem cell transplantation (hsct), and safety with blinatumomab versus chemotherapy. Max s. topp, md. the median overall survival (os) with the anti cd19 immunotherapy blinatumomab (blincyto) was 7.7 months versus 4 months with standard chemotherapy in patients with philadelphia. Topp, m, zimmerman, z, cannell, p, et al. health related quality of life (hrqol) of blinatumomab versus standard of care (soc) chemotherapy in patients with relapsed or refractory philadelphia. In an interview withtargeted oncology, topp, md, university hospital of wuerzburg, internal medicine, discusses the phase ii tower study, the findings of which showed that blinatumomab improves the overall survival of patients with relapsed refractory all from 4 months to 7.7 months. topp also discusses the future of blinatumomab as a possible.
Ecancer On Twitter Hot Off The Press Watch Prof Max Topp On Factors Topp, m, zimmerman, z, cannell, p, et al. health related quality of life (hrqol) of blinatumomab versus standard of care (soc) chemotherapy in patients with relapsed or refractory philadelphia. In an interview withtargeted oncology, topp, md, university hospital of wuerzburg, internal medicine, discusses the phase ii tower study, the findings of which showed that blinatumomab improves the overall survival of patients with relapsed refractory all from 4 months to 7.7 months. topp also discusses the future of blinatumomab as a possible. Study design and patients. the tower study design and primary study results were published previously [citation 14].in this prospective, randomized, phase 3, international study, investigators enrolled adults (18 years of age or older) with ph – bcp all that was refractory to chemotherapy, in first relapse after chemotherapy with a first remission <12 months, in second or greater relapse. Several clinical trials have evaluated the efficacy of blinatumomab in mrd positive b all patients. topp and colleagues conducted a phase ii study in which blinatumomab was administered to 21 patients in first cr after induction, and at least one round of consolidation chemotherapy, who had detectable mrd defined as ≥1 x 10 −4. the dose of.
Comments are closed.